However, recent clinical trials have shown that the drug has good efficacy in BRAF V600E mutant malignant astrocytomas and low-grade gliomas; patients with high expression of MMP14 may predict the better curative effect of vemurafenib treatment (Del et al., 2018; Van et al., 2018). This evidence concerns the gene BRAF and glioma.